ALSO NOTED: GSK to launch cervical cancer vaccine in EU;Ranbaxy licenses Sirtex cancer remedy;

> GlaxoSmithKline is now ready to launch its vaccine against cervical cancer, Cervarix, in the E.U--and analysts expect revenues of $2 billion to $5 billion there, based on rival Gardisil's performance in the U.S.  Report

> Ranbaxy Laboratories inked a licensing deal with Australia's Sirtex Medical to market the colorectal/liver cancer drug Sir-Spheres. Report

> Cardinal Health tapped CEO R. Kerry Clark as chairman, to replace retiring chairman and founder Robert D. Walker. Report

> Pfizer got EU approval for Celsentri (maraviroc), its new, first-in-class HIV fighter. Report

> Bristol-Myers will buy its drug-development partner Adnexus Therapeutics for about $415 million. Report

> Novartis got the E.U. nod for its Exelon patch, a treatment for mild to moderate Alzheimer's. Report

> The EU's drug safety committee recommended approval for Schering-Plough's combination hepatitis C treatment. Report

And Finally... Here's another drug safety dilemma to round out the day's news: Patients often take handfuls of different prescription drugs daily, in potentially deadly combinations, along with OTC chasers for good measure. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.